Efficacy and safety of camrelizumab combined with chemotherapy as second-line treatment for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma

Table 4 Multivariate analysis of PFs for second-line treatment in advanced ESCC patients

Characteristics	Multivariate Analysis
Characteristics	HR	95CI	P
ORR (CR + PR vs. SD + PD)	0.314	0.141 ∼ 0.699	0.005
DCR (CR + PR + SD vs. PD)	0.082	0.034 ∼ 0.203	<0.001
Previous Radical Surgery or not	1.184	0.666 ∼ 2.105	0.565
Treatment Plan (Camrelizumab Combined Chemotherapy vs. Chemotherapy)	0.892	0.500 ∼ 1.592	0.699

ISSN: 1477-7819